Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
HKF, as a subsidiary of Nanjing King-Friend, is a key international commercialization and distribution arm with several US FDA-approved generics, injectables, and biosimilars—including US launches such as eptifibatide and biosimilars for adalimumab, filgrastim, pegfilgrastim, and follitropin alpha—serving critical care, fertility, and autoimmune indications across multiple global regions[1][2][3][4][8].
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Hong Kong King-Friend Industrial.